Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021

Stock Price vs Company Growth
1d
1.3%
1w
0.7%
1m
3.4%
3m
1.4%
6m
41.5%
1y
18.5%
all
13.6%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 875 1.3%
740
1,019
Company Overview

Sales
873 Cr
Growth: 24.8%
Profit after Tax
198 Cr
Growth: -5.1%
Small Cap
7,040 Cr
P/E: 35.5x
Industry P/E: 32.5x
Fundamentals

Sales (Cr) ₹ 873
Growth 24.8%
EBITDA 33.2%
P/S 8.1x
Dividend 0.2%
P/E 35.5x
Book Value ₹ 2
PEG Ratio 1.4x
ROE 999.0%
P/B N/A
Shareholding Pattern

Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Investors (5)
Followers (1)